High plasma levels of the soluble form of CD30 activation molecule reflect disease activity in patients with Wegoner's granulomatosis

American Journal of Medicine

Volumn 102, Issue 6, 1997, Pages 517-523

  Wang, Guochun ^a   Hansen, Hinrich ^b   Tatsis, Efstratios ^a   Csernok, Elena ^a,c   Lemke, Hilmar ^b   Gross, Wolfgang L ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

^c Rheumaklinik Bad Bramstedt   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD30 ANTIGEN;

ADULT; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; REMISSION; RHEUMATOID ARTHRITIS; WEGENER GRANULOMATOSIS;

ANTIGENS, CD30; ARTHRITIS, RHEUMATOID; BACTERIAL INFECTIONS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; RADIOIMMUNOASSAY; SEVERITY OF ILLNESS INDEX; WEGENER GRANULOMATOSIS;

EID: 0030787761     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(97)00049-1     Document Type: Article

References (31)

1. Smith C, Davis T, Anderson D, et al. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science. 1990;248:1019-1023.
2. Dürkop H, Latza U, Hummel M, et al. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell. 1993;68:421-427.
3. Schwab U, Stein H, Gerdes J, et al. Production of a monoclonal antibody specific for Hodgkin's disease and a subset of normal lymphoid cells. Nature. 1982;299:65-67.
4. Stein H, Mason DY, Gerdes J, et al. The expression of Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that the Reed Sternberg cells and histiocytic malignancies are derived from activated T (helper) lymphoblasts. Blood. 1985;66:848-858.
5. Andressen R, Osterholz J, Lohr GW, Bross KJ. A Hodgkin's cell-special antigen is expressed on a subset of auto-and alloreactive T (helper) lymphocytes. Blood. 1984;63:1299-1302.
6. Ellis TM, Simms PE, Slivnick DJ, et al. CD30 is a signal transducing molecule that defined a subset of human activated CD45RO+ T cells. J Immunol. 1993;151:2380-2389.
7. Alzona M, Jäck HM, Fisher RI, Ellis TM. CD30 defines a subset of activated human T cells that produce IFN-γ and IL-5 and exhibit enhanced B cell helper activity. J Immunol. 1994;153:2861-2867.
8. Falini B, Pilieri S, Pizzolo G, et al. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood. 1995;85:1-14.
9. Romagnani S. Biology of human Th1 and Th2 cells. J Clin Immunol. 1995;15:121-129.
10. Peter GD, Carli MD, Almerigogna F, et al. Preferential expression of CD30 by human CD4+ T cells producing Th2-type cytokines. FASEB J. 1995;9:81-86.
11. Hansen HP, Kisseleva T, Kobarg J, et al. A zinc metalloproteinase is responsible for the release of CD30 on human tumor cell lines. Int J Cancer. 1995;63:750-756.
12. Caligaris-Cappio F, Bertero MT, Converso M, et al. Circulating levels of soluble CD30, a marker of cells producing Th2-type cytokines, are increased in the patients with systemic lupus erythematosus and correlate with disease activity. Clin Exp Rneum. 1995;13:339-343.
13. Pizzolo G, Vinante F, Morosato L, et al. High serum level of the soluble form of CD30 molecule in the early phase of HIV-1 infection as an independent predictor of progression to AIDS. AIDS. 1994;8:741-745.
14. Gerli R, Muscat C, Bistoni O, et al. High levels of the soluble form of CD30 molecule in rheumatoid arthritis (RA) are expression of CD30+ T cell involvement in the inflamed joints. Clin Exp Immunol. 1995;102:547-550.
15. Fattovich G, Vinante F, Giustina G, et al. Serum levels of soluble CD30 in chronic hepatitis B virus infection. Clin Exp Immunol. 1996;103:105-110.
16. Walton EW. Giant cell granuloma of the respiratory tract (Wegener's granulomatosis). Br Med J. 1958;2:265-270.
17. DeRemee RA, McDonald TJ, Harrison EG Jr, Coles DT. Wegener's granulomatosis: anatomic correlates, a proposed classification. Mayo Clin Proc. 1976;51:777-781.
18. Reinhold-Keller E, DeGroot K, Rudert H, et al. Response to trimethoprim/ sulfamethoxazole in Wegener's granulomatosis depends on the phase of disease. QJM. 1996;89:15-23.
19. Gross WL. New concepts in Wegener's granulomatosis. In: Ansell BM, Bacon PA, Lie JT, Yazici H, eds. The Vasculitides. London: Chapman & Hall; 1996;145-170.
20. Brouwer E, Stegeman CA, Huitema MG, et al. T cell reactivity to proteinase 3 and myeloperoxidase in patients with Wegener's granulomatosis. Clin Exp Immunol. 1994;98:448-453.
21. Mathieson PW, Oliveira DBG. The role of cellular immunity in systemic vasculitis. Clin Exp Immunol. 1995;100:183-185.
22. Schmitt WH, Heesen C, Csernok E, et al. Elevated serum levels of soluble interleukin-2 receptor in patients with Wegener's granulomatosis. Arthritis Rheum. 1992;35:1088-1096.
23. Ballieux BE, van der Burg SH, van der Woude FJ, et al. Cell-mediated autoimmunity in patients with Wegener's granulomatosis. Clin Exp Immunol. 1995;100:186-193.
24. Leavitt RY, Fauci AS, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum. 1990;33:1101-1107.
25. Jennette CJ, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum. 1994;37:187-192.
26. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-324.
27. Reinhold-Keller E, Kekow J, Schnabel A, et al. Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis. Arthritis Rheum. 1994;37:919-924.
28. Nölle B, Specks U, Lüdemann J, et al. Anti-cytoplasmic antibodies: their immunodiagnostic value in Wegener's granulomatosis. Ann Intern Med. 1989;111:28-40.
29. Csernok E, Szymkowiak C, Wang GC, et al. T-cell cytokine profiles in patients with Wegener's granulomatosis. Arthritis Rheum. 1995;38: S375.
30. Rubin LA. The soluble interleukin-2 receptor in rheumatic disease. Arthritis Rheum. 1990;33:1145-1148.
31. Waldmann T. The IL-2/IL-2 receptor system: a target for rational immune intervention. Immunol Today. 1993;14:264-270.